News | May 17, 2025
IOL Chemicals and Pharmaceuticals posts Q4 FY25 PAT at Rs. 31.42 Cr
IOL Chemicals and Pharmaceuticals has posted net profit of Rs.101.07 crores for the Financial Year ended March 31, 2025
IOL Chemicals and Pharmaceuticals has posted net profit of Rs.101.07 crores for the Financial Year ended March 31, 2025
This approval authorizes the company to export Ibuprofen to the Chinese markets
This change is subject to the approval of the shareholders of the company, the Ministry of Corporate Affairs and other statutory and regulatory authorities,
Strengthening capabilities in Peptide Therapeutics and CDMO services
USFDA inspection at Alembic Pharma's Bioequivalence facility
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
_256_384.jpg)
Mesalazine is used to treat inflammatory bowel disease
Subscribe To Our Newsletter & Stay Updated
